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Eﬃcacy and safety of intermittent preventive treatment
with sulfadoxine-pyrimethamine for malaria in African
infants: a pooled analysis of six randomised,
placebo-controlled trials
John J Aponte, David Schellenberg, Andrea Egan, Alasdair Breckenridge, Ilona Carneiro, Julia Critchley, Ina Danquah, Alexander Dodoo,
Robin Kobbe, Bertrand Lell, Jürgen May, Zul Premji, Sergi Sanz, Esperanza Sevene, Rachida Soulaymani-Becheikh, Peter Winstanley, Samuel Adjei,
Sylvester Anemana, Daniel Chandramohan, Saadou Issifou, Frank Mockenhaupt, Seth Owusu-Agyei, Brian Greenwood, Martin P Grobusch,
Peter G Kremsner, Eusebio Macete, Hassan Mshinda, Robert D Newman, Laurence Slutsker, Marcel Tanner, Pedro Alonso, Clara Menendez

Summary

Background Intermittent preventive treatment (IPT) is a promising strategy for malaria control in infants. We
undertook a pooled analysis of the safety and eﬃcacy of IPT with sulfadoxine-pyrimethamine in African infants.
Methods We pooled data from six double-blind, randomised, placebo-controlled trials (undertaken one each in
Tanzania, Mozambique, and Gabon, and three in Ghana) that assessed the eﬃcacy of IPT with sulfadoxinepyrimethamine in children. In all trials, IPT or placebo was given to children at the time of routine vaccinations
delivered by WHO’s Expanded Program on Immunization. Data from the trials for incidence of clinical malaria, risk
of anaemia (packed-cell volume <25% or haemoglobin <80 g/L [A: converted to SI units, ok?]), and incidence of
hospital admissions and adverse events in infants up to 12 months of age were reanalysed by use of standard outcome
deﬁnitions and time periods [A: ok?]. Analysis was by modiﬁed intention to treat, including all infants who received
at least one dose of IPT or placebo. [A: please check that all edits in this section are correct]
Findings The six trials provided data on 7930 infants (IPT, n=3958; placebo, n=3972). IPT had a protective eﬃcacy of
30·3% (95% CI 19·8–39·4, p<0·0001) against clinical malaria, 21·3% (8·2–32·5, p=0·002) against the risk of anaemia,
38·1% (12·5–56·2, p=0·007) against hospital admissions associated with malaria parasitaemia, and 22·9% (10·0–34·0,
p=0·001) against all-cause hospital admissions. [A: edit ok?] There were 56 deaths in the ITP group compared with
53 in the placebo group (rate ratio 1·05, 95% CI 0·72–1·54, p=0·79). One death was judged possibly related to study
treatment (IPT group). Four of 676 non-fatal hospital admissions in the IPT group were deemed related to study
treatment compared with ﬁve of 860 in the placebo group. None of three serious dermatological adverse events in the
IPT group were judged related to study treatment compared with one of 13 in the placebo group. [A: edits ok?]
Interpretation IPT with sulfadoxine-pyrimethamine in infants was safe and eﬃcacious across a range of malaria
transmission settings, suggesting that this intervention is a useful contribution to malaria control.
Funding Bill & Melinda Gates Foundation.

Introduction
Plasmodium falciparum malaria is a major cause of
disease and death in children in sub-Saharan Africa, and
improved control measures are urgently needed.
Intermittent preventive treatment (IPT) is the
administration of a full course of an antimalarial drug at
speciﬁed timepoints, whether or not parasites are
present. Previous studies have shown that continuous
chemoprophylaxis in infants reduces morbidity and
mortality caused by malaria. However, this approach has
not been implemented in endemic countries because of
the major logistical challenges involved and fears that
large-scale drug use would hasten the spread of drug
resistance and impair the development of naturally
acquired antimalarial immunity.1–5 Since IPT in infants is
associated with lower drug exposure than is
chemoprophylaxis, the eﬀect of IPT on the spread of
www.thelancet.com Vol 374

resistance and impairment of the development of
immunity might also be lower. Furthermore, logistical
challenges could be reduced by giving IPT to infants at
the time of routine vaccinations delivered through
WHO’s Expanded Program on Immunization (EPI).
Sulfadoxine-pyrimethamine [A: Our house style is not
to abbreviate drug names] could be useful for IPT in
infants because this combination is available, aﬀordable,
well tolerated, and already recommended for IPT in
pregnancy.6,7 The long half-life of sulfadoxinepyrimethamine could produce an extended prophylactic
eﬀect and enables the combination to be given as a single
dose, which can be supervised. From 1999 to 2007, six
randomised, placebo-controlled trials of IPT with
sulfadoxine-pyrimethamine were completed.8–13 These
trials assessed the eﬀect of three or four doses of IPT on
malaria in early childhood. Since the study designs
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diﬀered in terms of dosing schedule, primary endpoints,
and duration of follow-up, we were unable to compare
the trials using the published results. We therefore
reanalysed the data using standardised outcome
deﬁnitions and time periods to generate a meaningful
pooled analysis of the safety and eﬃcacy of IPT given to
infants at the time of routine immunisation. We also
investigated whether there was a potential increase in
morbidity in the period after the intervention.

The dosing schedule for IPT and placebo diﬀered
between the trials (ﬁgure 1). Doses of IPT were given
according to bodyweight in the trials in Ifakara and
Manhiça, according to dose number in the trial in
5 Navrongo, and as a ﬁxed dose in the trials in Kumasi,
Lambaréné, and Tamale. One tablet contained 500 mg
sulfadoxine and 25 mg pyrimethamine. All six trials had
received ethical approval.
Safety and eﬃcacy were assessed by passive clinical
10 surveillance in all trials. Additionally, active detection of
Methods
malaria and anaemia was done every month in the trials
[A: please note, subheadings changed to conform with in Lambaréné and Kumasi, and every 3 months in the
Lancet style]
trial in Tamale (ﬁgure 1); in Lambaréné, a blood sample
Search strategy and selection criteria
was taken only if the child was febrile, whereas in
This analysis was led by the IPTi Consortium, made up 15 Kumasi and Tamale, the sample was taken irrespective
of autonomous research institutions, WHO, and of the presence of symptoms. In the trial in Lambaréné,
UNICEF, and assembled to assess IPT in infants as a safety was reviewed 1 week after every dose; a blood
potential public health tool.14–16 [A: URL corrected, ok?]] sample was taken if the child was febrile. In the trial in
An independent consortium safety panel and a statistical Manhiça, safety assessment was enhanced by home
working group (webappendix) were convened to under- 20 visits 1 week after every dose, registration of
take pooled analyses of safety and eﬃcacy, respectively. dermatological complaints of children attending a health
In 2005, the IPTi Consortium invited the principal facility, and blood tests 1 month after the second dose of
investigator of every completed or continuing trial of IPT IPT or placebo [A: ok?]. In the trial in Navrongo, 20% of
with sulfadoxine-pyrimethamine in infants to take part infants were visited within 4 weeks of IPT or placebo
in the pooled analyses. Trials were eligible for inclusion if 25 administration so that side-eﬀects could be assessed.
they had randomly assigned asymptomatic children
Thick blood ﬁlms were stained and read by use of
(younger than 1 year) who were attending routine health standard procedures. Parasite density was calculated on
contacts to either IPT with sulfadoxine-pyrimethamine the assumption of a mean [A: ok? Since average can
or placebo. [A: edit ok? Placebo had not been mentioned] mean medium or mean] of 8000 leucocytes per µL in all
We did not include trials of intermittent treatment that 30 trials, apart from the one in Lambaréné, where a volumeused diﬀerent drugs, did not deliver IPT alongside EPI based method was used.17
vaccinations, used IPT as a treatment for anaemia, or
The presence of anaemia was determined by packedgave IPT at monthly intervals to schoolchildren or cell volume measured in microcapillary tubes in the trials
children less than 10 years of age in settings with highly in Ifakara, Navrongo, and Manhiça, and by haemoglobin
seasonal transmission of malaria. These pooled analyses 35 concentration measured with a HemoCue photometer in
include all six eligible trials of IPT with sulfadoxine- the trials in Kumasi (HemoCue, Derbyshire, UK) and
pyrimethamine in infants published up to May, 2009.8–13 Tamale (HemoCue, Angelholm, Sweden). In the trial in
A PubMed search for randomised controlled trials of Lambaréné, full blood counts were undertaken on an
infants 1–23 months old with the key words “intermittent“, Abbott Cell-Dyn 3000 device (Abbott Diagnostics, Santa
“treatment“, “malaria“, and “infants” did not ﬁnd any 40 Clara, CA, USA). There is no accepted common deﬁnition
additional studies that met our eligibility criteria.
of anaemia in children under 6 months of age; therefore,
a cut-oﬀ that was common among trials was used
Patients, study design, and procedures
(packed-cell volume <25% or haemoglobin <80 g/L).
The six randomised controlled trials, described in detail
elsewhere, are summarised in table 1 and ﬁgure 1. [A: 45 Statistical analysis
references have been renumbered so that they appear in An analytical plan was agreed by all investigators before
order of mention in table 1. Please check throughout the reanalysis started. Data were reanalysed at the
carefully] The trials were undertaken in Ifakara in individual level. To enable a pooled analysis, outcome and
Tanzania, Manhiça in Mozambique, Lambaréné in follow-up deﬁnitions were based on information common
Gabon, and Navrongo, Kumasi, and Tamale, in Ghana, 50 to all trials; therefore, results do not necessarily correspond
and assessed the eﬃcacy of IPT with sulfadoxine- with those in reports published for each study. Analysis
pyrimethamine for prevention of clinical malaria and was by modiﬁed intention to treat, including all children
anaemia during the ﬁrst or second year of life, or both. who received at least one dose of IPT or placebo up to the
Block randomisation by individual was done in all trials follow-up times deﬁned in table 2. We examined the eﬀect
apart from the one in Navrongo, which was cluster- 55 of the IPT intervention during the 35 days after a dose to
randomised by community. All trials were double-blind. assess the prophylactic beneﬁt of sulfadoxine[A: ok?]
pyrimethamine. We chose this interval because, according
1
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Ifakara8

Navrongo9

Manhiça10

Kumasi11

Tamale12

Lambaréné13

Country

Tanzania

Ghana

Mozambique

Ghana

Ghana

Gabon

Recruitment years

1999–2000

2000–02

2002–04

2003–05

2003

2002–04

Pattern of malaria transmission

Perennial

Highly seasonal

Perennial with seasonal peaks Perennial with seasonal Perennial with
peaks
seasonal peaks

Perennial with
seasonal peaks

Insecticide-treated bednet use in trial nn/NN (67%)
participants (n/N [%]) [A1]

nn/NN (18%)

nn/NN (0%)

nn/NN (3%)†

nn/NN (5%)

Oﬃcial ﬁrst-line treatment for
uncomplicated malaria

Chloroquine or sulfadoxinepyrimethamine

Chloroquine

Chloroquine and sulfadoxine- Chloroquine
pyrimethamine

Chloroquine

Chloroquine

Actual drug used in trial [A: ok?] for
treatment of uncomplicated malaria

Sulfadoxine-pyrimethamine

Chloroquine
10

Quinine

Amodiaquine and
artesunate

Artesunate

Amodiaquine
and artesunate

Sulfadoxine-pyrimethamine in-vivo
failure at 14 days in symptomatic
6–59-month old children (% [date
assessed] [A: ok?])

31% (1999–2000)

22% (2004)

21% (2001)

Not available

14% (2002)

21% (2004)

Iron supplementation

Unsupervised

5

nn/NN (2%)*

Unsupervised
15

None

None

None

None

HIV prevalence (not measured in trial 6% in ANCs in Ifakara
participants or their mothers, %)

About 2% in ANCs

23% in ANCs in Manhiça

2·7% in ANCs

About 2–3% in
ANCs

7·5% [A: in
which
population?]

Randomisation

Individual

Cluster

Individual

Individual

Individual

Individual

Dose of IPT with sulfadoxinepyrimethamine‡

According to bodyweight
(<5 kg, quarter of a tablet;
5–10 kg, half a tablet; >10 kg,
one tablet)

According to dose number
20
(half a tablet for ﬁrst and
second doses, one tablet for
third and fourth doses)

According to bodyweight
(<5 kg, quarter of a tablet;
5–10 kg, half a tablet; >10 kg,
one tablet)

Fixed (half a tablet at
each dose)

Fixed (half a
tablet at each
dose)

Fixed (half a
tablet at each
dose)

Passive case detection

Yes

Yes

Yes

Yes

Yes

Yes

Active case detection

No

No

No

Monthly

Every
3 months

Monthly

25

Number of children (modiﬁed
ITT population)§ [A1]
IPT

350

1221

748

535

600

504

Placebo

351

1225

755

535

599

507

Incidence of clinical malaria
(episodes per person-years at risk)¶

0·54

1·10

0·79

1·27

0·95

0·16

Risk of anaemia (of the ﬁrst or only
episode, %)||

8·6%

6·3%

10·6%

37·6%

31·7%

15·7%

30

ANC=antenatal clinic. IPT=intermittent preventive treatment. ITT=intention-to-treat. *According to Ghana Demographic and Health Survey, 2003. †Bednet use in 2001 in trial area—not necessarily
insecticide-treated nets. ‡Manufacturer of sulfadoxine-pyrimethamine and placebo was La Roche ([A: town, country?]) in all trials apart from the one in Navrongo, where it was Cosmos Pharmaceuticals
35 one dose of study drug. [A1: is this ok? ie, the ITT population, rather than the total number of children in the trials?]
(A: town?], Nairobi). §Modiﬁed ITT population includes all children who received at least
¶In the placebo group, from ﬁrst dose until 12 months of age; history of fever or measured fever with any Plasmodium falciparum parasitaemia. History of fever included reported fever during the past 24 h in
the trials in Ifakara and Manhiça, and during the past 48 h for the other four trials. Measured fever was deﬁned as an axillary temperature 37·5°C or more for trials in Ifakara, Navrongo, Tamale, and Manhiça;
rectal or tympanic temperature 38°C or more for the trial in Kumasi, and 38·5°C or more for the trial in Lambaréné. ||In the placebo group, from ﬁrst dose until 12 months of age; packed-cell volume less than 25%
in trials in Ifakara, Navrongo, and Manhiça, and a haemoglobin concentration less than 80 g/L in the trials in Kumasi, Lambaréné, and Tamale. [A1: please provide numerators and denominators to
accompany %s for ITN use]
40

Table 1: Characteristics of six trials of IPT with sulfadoxine-pyrimethamine versus placebo in infants

to the elimination half-life reported by the manufacturer, deﬁnitions see table 2). [A:is this ok to add here?] Infants
residual sulfadoxine plasma concentrations after 5 weeks were not deemed at risk for 21 days after a clinical malaria
are less than 5%, which is consistent with negligible 45 episode, hospital admission, or receipt of an antimalarial
inhibitory activity.18 [A: please mention that the potential treatment. This 21-day period was selected to avoid overlap
rebound eﬀect was examined, and why]
with the 28-day period for active detection visits in the
Negative binomial regression, which allows for potential trials in Kumasi and Lambaréné. The eﬀect of IPT on the
clustering of episodes within individuals, was used to relative risk of at least one episode of anaemia, with as the
investigate the eﬀect of IPT on the incidence of all 50 denominator the number of children at risk from the ﬁrst
episodes of clinical malaria, clinical malaria with a locally dose until 12 months of age, was analysed by use of a
sensitive case deﬁnition,19 all-cause hospital admissions, Poisson regression model, with log-link and a robust
and hospital admissions associated with microscopically error variance.20
conﬁrmed [A: correct?] malaria parasitaemia. To allow for
The eﬃcacy of IPT was deﬁned as (1–RR)×100, where
clustering across individuals within the trial in Navrongo, 55 RR is the relative rate or relative risk [A: since relative
robust SEs were used. Incidence was calculated as the risk can mean rate ratio or risk ratio, please deﬁne which
number of episodes divided by the time at risk (for is used]. Combined estimates were obtained by metawww.thelancet.com Vol 374
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to be related to sulfadoxine-pyrimethamine, apart from
in the trial in Kumasi where all adverse events that
occurred within 8 weeks of treatment were deemed
Ifakara8
x
x
possibly related to study drug. Serious adverse events
3
4
1 2
5 that occurred more than 3 months after the last dose of
Navrongo9
x x x
x
x
study drug were deemed very unlikely to be related to
1 2
3
treatment and excluded from these analyses.
Manhiça10
x
x
x
x
The number of deaths, non-fatal hospital admissions,
1
2
3
serious dermatological adverse events [A: why were only
Kumasi11
x x x x x x x x x x x x x x x x x x x x x x
10 dermatological adverse events analysed?], total sample
1
2
3
size, and person-time at risk were extracted by principal
12
Tamale
x
x
x
x
x
x
x x x x
investigators or statisticians and reviewed by the
1
2
3
consortium safety panel. A meta-analysis was done on
13*
Lambaréné
x x x x x x x x x x x x x x x x x x x x x x
the risk of mortality by use of Review Manager version
15 5.0 or StatsDirect version 2.7.1 software. The numerator
3
6
9
12
15
18
21
24
was the number of deaths, and the denominator was the
Age (months)
number of infants who received at least one dose of IPT
Figure 1: Schedules of study treatment and follow-up visits
or placebo [A: ok?]. The pooled rate ratio was calculated
Vertical bars represent the age when intermittent preventive treatment with sulfadoxine-pyrimethamine or
by the DerSimonian-Laird method. For the trial that was
placebo was given (and number of dose). *Follow-up in the trial in Lambaréné was up to 30 months of age.
20 cluster randomised, the rate ratio and SE of the rate ratio
analysis with random eﬀects, and as weight for each trial were estimated by use of a robust cluster method. The
the inverse of the SE of the estimated RR in the cluster-adjusted SE was identical to the unadjusted SE.
logarithmic scale. To assess the eﬀect of an individual
Heterogeneity between trials was assessed by visual
trial in the meta-analysis, sensitivity analyses were done inspection of forest plots of the eﬀects and 95% CIs for
in which one study at a time was removed from the 25 each site, calculation of a χ² test for heterogeneity
analysis. Analyses were done with Stata version xx (statistical signiﬁcance at 10% level), and calculation of
software. [A: version number?]
the I² statistic (which quantiﬁes the amount of heteroStandard WHO deﬁnitions were used for adverse geneity over and above that expected due to chance alone
events and for the grading of severity.21 In all trials apart on a scale from 0% to 100%).22 Fixed-eﬀect meta-analysis
from the one in Kumasi, a serious adverse event was 30 was used to pool data for this outcome measure.
deﬁned as a hospital admission or death. In the trial in
Kumasi, a life-threatening event or enduring disability Role of the funding source
was also judged as a serious adverse event (in the other The sponsor of the study had no role in study design,
trials, a patient with a life-threatening event would be data collection, data analysis, data interpretation, or
admitted to hospital [A: edit ok?]). Assessment of causality 35 writing of the report. The corresponding author had full
was made by the on-site principal investigator or access to all the data in the study and had ﬁnal
physician. Causality was assessed on symptoms known responsibility for the decision to submit for publication.

x

1

1

A cross-sectional or active case detection visit

3

2

Start of time at risk

40

End of time at risk

Eﬃcacy (clinical malaria, hospital admissions, anaemia)
Primary

Dose 1 of IPT or placebo

12 months of age

Secondary

Dose 1 of IPT or placebo

3 months after the last dose of IPT or placebo

Prophylactic eﬀect I

Dose of IPT or placebo at 3 months of age*

35 days after start of time at risk

Prophylactic eﬀect II

Dose of IPT or placebo at 9 months of age†45

35 days after start of time at risk

Prophylactic eﬀect III

Dose of IPT or placebo at 12 months or 15 months of age‡

35 days after start of time at risk

Inter-dose eﬀect

35 days after the dose of IPT or placebo at 3 or 4 months of age

Dose of IPT or placebo at 9 months of age

Potential rebound I

35 days after the dose of IPT or placebo at 9 months of age

15 months of age or the next dose of IPT or placebo§

Potential rebound II

35 days after the last dose of IPT or placebo¶

5 months after start of time at risk

50

Safety (deaths, adverse eﬀects)
Primary

Dose 1 of IPT or placebo

3 months after the last dose given or 12 months of age

IPT=intermittent preventive treatment. * Dose 2 in the trial in Ifakara, dose 1 in the other trials. †Dose 3 in the trials in Ifakara, Navrongo, and Manhiça; dose 2 in the trials in
Kumasi, Tamale, and Lambaréné. ‡Dose 4 in the trial in Navrongo at 12 months; dose 3 in the trials in Kumasi, Tamale, and Lambaréné at 15 months of age. §Next dose at
12 months of age in the trial in Navrongo, and 15 months of age in the trials in Kumasi, Tamale, and Lambaréné. ¶Last dose was at 9 months of age in the trials in Ifakara and
Manhiça, at 12 months of age in the trial in Navrongo, and at 15 months of age in the55
trials in Kumasi, Tamale, and Lambaréné. [A: “or placebo” added to all—ok?]

Table 2: Risk periods for each analysis

4

www.thelancet.com Vol 374

Articles

1

Ifakara8

Navrongo9

Manhiça10

Kumasi11

Tamale12

Lambaréné13

Primary deﬁnition*

59·4% (41·7 to 71·7)

30·3% (17·8 to 40·9)
5

20·8% (3·5 to 35·0)

20·7% (8·7 to 31·2)

32·4% (19·6 to 43·2)

22·6% (–24·2 to 51·7)

Locally deﬁned cut-oﬀ density†

61·9% (43·5 to 74·3)

32·3% (16·9 to 44·8)

30·9% (14·4 to 44·3)

22·7% (9·2 to 34·1)

27·4% (4·7 to 44·6)

29·2% (–15·1 to 56·5)

High-density cut-oﬀ‡

From dose 1 until 12 months of age
Clinical malaria

56·3% (25·3 to 74·5)

33·2% (14·0 to 48·1)

26·6% (6·5 to 42·4)

18·4% (–15·1 to 42·2)

26·0% (–22·0 to 55·1)

26·2% (–49·0 to 63·5)

All-cause hospital admissions

29·0% (6·6 to 46·1)

18·3% (0·3 to 33·1)

24·9% (6·6 to 39·7)

17·8% (–22·5 to 44·8)

49·8% (18·5 to 69·0)

–35·8% (–142·3 to 23·9)

Hospital admissions associated
with malaria parasitaemia§

58·3% (28·4 to 75·8)

52·1% (29·5 to 67·5)

20·3% (–19·9 to 47·0)

–6·6% (–103·1 to 44·1)

44·5% (–80·1 to 82·9)

Anaemia (reduced risk of ﬁrst or
only episode)¶

49·9% (8·4 to 72·5)

11·1% (–4·5 to 24·4)

17·0% (0·8 to 30·5)

10

46·5% (21·2 to 63·7)

5·4% (–27·5 to 29·8)

··
25·2% (–2·7 to 45·5)

Against clinical malaria (primary deﬁnition) on diﬀerent follow-up times
Prophylactic eﬀect||
I (after dose at 3 months of age)

77·7% (–3·0 to 95·2)

75·6% (49·6 to 88·2)

57·5% (20·6 to 77·3)

82·0% (61·8 to 91·5)

83·0% (12·8 to 96·7)

74·8% (–125·5 to 97·2)

II (after dose at 9 months of age)

91·1% (62·1 to 97·9)

79·3% (69·5 to 85·9)

65·2% (37·1 to 80·7)

47·6% (17·1 to 66·8)

97·6% (90·5 to 99·4)

72·9% (–53·2 to 95·2)

29·7% (–5·1 to 52·9)

90·6% (79·7 to 95·6)

77·5% (–100·9 to 97·5)

III (after dose at 12 or 15 months
of age)

··

15

73·7% (57·6 to 83·7)

··

Inter-dose eﬀect period**

42·4% (–1·2 to 67·3)

12·9% (–6·8 to 29·0)

–8·0% (–39·3 to 16·3)

11·5% (–6·1 to 26·2)

19·6% (–0·2 to 35·5)

11·2% (–62·9 to 51·6)

Potential rebound period I††

29·0% (–4·2 to 51·6)

–3·4% (–29·3 to 17·5)

7·4% (–13·4 to 24·4)

7·8% (–9·1 to 22·1)

19·6% (–2·2 to 36·7)

12·7% (–54·9 to 50·8)

Clinical malaria (primary deﬁnition)

30·3% (1·0 to 50·9)

0·2% (–20·3 to 17·1)

–11·0% (–45·0 to 15·0)

All-cause hospital admissions

–7·9% (–51·9 to 23·4) –16·5% (–54·0 to 11·9)

Hospital admissions associated
with malaria parasitaemia

11·3% (–74·4 to 54·9)

Potential rebound period II‡‡

Anaemia (reduced risk of ﬁrst or
only episode)

20

–8·6% (–79·5 to 34·3)

2526·3)
40·0% (–11·8 to 67·8) –24·2% (–105·0 to

–5·8% (–24·0 to 9·8)

–0·3% (–18·9 to 15·4)

–36·3% (–147·3 to 24·9)

8·4% (–25·6 to 33·2)

–19·8% (–108·0 to 31·0)

24·6% (–21·5 to 53·3)

–1·4% (–115·7 to 52·3)

–36·1% (–117·4 to 14·8)

–47·7% (–261·2 to 39·6)

–74·5% (–496·1 to 48·9)

10·8% (–36·4 to 41·7)

–2·5% (–22·9 to 14·6)

3·4% (–9·9 to 15·1)

··
–15·1% (–154·3 to 47·9)

··=data not available. IPT=intermittent preventive treatment. Data are % protective eﬃcacy (95% CI). Protective eﬃcacy deﬁned as (1–RR)×100. [A: ok?] *Primary deﬁnition: history of fever or measured fever
with any P falciparum parasitaemia. History of fever included reported fever during the past 24 h in the trials in Ifakara and Manhiça, and during the past 48 h for the other four trials. Measured fever was deﬁned
as an axillary temperature 37·5°C or more for the trials in Ifakara, Navrongo, Tamale, and Manhiça; rectal or tympanic temperature 38°C or more for the trial in Kumasi, and 38·5°C or more for the trail in
Lambaréné. †A history of fever, or measured fever, with a minimum P falciparum parasite
30 density for each site chosen to have a speciﬁcity more than 90%; trials in Ifakara, Manhiça, and Kumasi more than
500 parasites per µL; trial in Lambaréné more than 600 parasites per µL; trial in Tamale more than 5000 parasites per µL; trial in Navrongo more than 8000 parasites per µL. ‡Episodes with a history of fever or
measured fever with P falciparum parasitaemia more than 20 000 parasites per µL. §Admissions to a paediatric ward with any P falciparum parasitaemia irrespective of symptoms suggestive of malaria or a clinical
diagnosis of malaria. ¶Packed-cell volume less than 25% in the trials in Ifakara, Navrongo, and Manhiça, and a haemoglobin concentration less than 80 g/L in the trials in Kumasi, Lambaréné, and Tamale. ||See
table 2 for deﬁnitions. **From 35 days after dose at 3 months or 4 months of age until dose at 9 months of age. ††From 35 days after the dose at 9 months of age up to the next dose of IPT or age
15 months. ‡‡5-month period starting 35 days after last dose. [A: please check all footnotes are cited correctly]
35
Table 3: Protective eﬃcacies of IPT with sulfadoxine-pyrimethamine in infants

Results

to non-signiﬁcant levels, and the combined eﬃcacy
[A: to conform with journal style, subheadings have been estimate to 25·9% (19·6–31·7%, p<0·001; table 4).
deleted from this section. Also, to avoid repetition, any 40 [A: please provide exact p value unless p<0·0001] Detailed
data in the text that is clearly shown in the tables and information about each analysis, including the total
ﬁgures has been deleted]
number of events and person-years at risk, total number
This analysis is based on data from 7930 infants (IPT, of children in each site and outcome, as well as other
n=3958; placebo, n=3972) in all six trials of IPT with analyses are provided in the webappendix.
sulfadoxine-pyrimethamine in infants published up to 45 The eﬀect of IPT on the relative risk of anaemia in
May, 2009. Reported baseline characteristics were similar infants ranged from 5·4% to 49·9%, with moderate
between IPT and placebo groups in all the trials. [A: heterogeneity between trials (I²=46·9%). The combined
please provide a table showing the baseline characteristics eﬃcacy estimate for risk of anaemia was 21·3%
of the two groups]
(8·2–32·5, p=0·002; table 4).
Table 3 shows the estimates of eﬃcacy of IPT in infants 50 IPT had protective eﬃcacies of 22·9% (10·0–34·0,
up to 12 months of age in the individual trials. The p=0·001) against all-cause hospital admissions and
combined estimate of protective eﬃcacy against the 38·1% (12·5–56·2, p=0·007) and for hospital admissions
primary deﬁnition of clinical malaria in children aged up associated with malaria parasitaemia (table 4). The
to 12 months was 30·3% (95% CI 19·8–39·4, p<0.0001; heterogeneity between trials for these two outcomes was
ﬁgure 2 and table 4). There was signiﬁcant heterogeneity 55 moderate (I²=33·5% and 49·6%, respectively); however,
between trials (I²=61·8%). Removal of the trial with the removing the trial with the highest protective eﬃcacy
highest protective eﬃcacy (Ifakara) reduced heterogeneity made little diﬀerence to the estimates (table 4).
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condition but died the next night at home. The most
probable cause of death was sepsis with complications of
recent malaria and severe anaemia.
10·0
Ifakara
59·4 (41·7 to 71·7)
Four of 676 non-fatal hospital admissions in the IPT
5 group were deemed related to study treatment (assigned
Navrongo
30·3 (17·8 to 40·9)
21·1
while the trials were masked), compared with ﬁve of
20·8 (3·5 to 35·0)
18·7
Manhiça
860 in the placebo group. [A: edit ok?] In the trial in
22·9
Kumasi
20·7 (8·7 to 31·2)
Kumasi, causality could not be assessed for ﬁve hospital
admissions (IPT, n=3; placebo, n=2) because hospital
32·4 (19·6 to 43·2)
20·5
Tamale
10 ﬁles were missing.
22·6 (–24·2 to 51·7)
6·8
Lambaréné
Three serious dermatological adverse events were
reported in the IPT group; however, none of these was
30·3 (19·8 to 39·4)
100·0
Overal protective eﬃcacy
judged related to study treatment (table 5). Of 13 serious
dermatological adverse events in the placebo group, one
–100
–75
–50
–25
0
25
50
75
100
15 was classiﬁed as possibly related to study drug, since it
Favours placebo
Favours IPT
occurred within 3 weeks after a dose. At the time of the
Figure 2: Combined estimates for the protective eﬃcacy of IPT with sulfadoxine-pyrimethamine in infants
second dose of study treatment at 9 months of age, the
against clinical malaria from dose 1 up to 12 months of age
infant had malaria and received artesunate-amodiaquine
The width of the diamond represents the 95% CI interval in the overall pooled protective eﬃcacy estimate.
(in addition to study treatment) but was not admitted to
[A: vertical line moved to 0%. Ok?]
20 hospital. The infant developed bullous skin lesions
Prophylactic eﬀects I, II, and III are the 35-day intervals 3 weeks later. Another infant in the placebo group was
following the doses at 3 months, 9 months, and 12 or diagnosed with Stevens–Johnson syndrome and died at
15 months of age, respectively. During prophylactic eﬀect the age of 5 months from multiple organ failure,
I, the incidence of clinical malaria was between 57·5% 2 months after the ﬁrst dose of study treatment. The
and 83·0% lower in the IPT group than in the placebo 25 infant was HIV-positive and had been started on agents
group [A: is this edit correct—ie, these were the % known to be associated with Stevens–Johnson syndrome
diﬀerences?] (table 3). Malaria incidence was 47·6–97·6% (antituberculosis
drugs
[isoniazid,
rifampicin,
and 29·7–90·6% lower in the ITP group than in the pyrazinamide, and ethambutol] and co-trimoxazole)
placebo group during prophylactic eﬀects II and III, 5 days before the onset of dermatological symptoms. The
respectively. [A: is this edit correct?] Analyses of the inter- 30 child had not been admitted to hospital.
dose eﬀect (35 days after the IPT or placebo dose at 3 or
4 months of age until the dose at 9 months of age) varied Discussion
between trials with borderline signiﬁcant eﬃcacy in the [A: any repetition of Introduction and Results sections
trials in Ifakara and Tamale, but no eﬀect was seen in the has been deleted] This pooled analysis of six randomised,
other trials.
35 placebo-controlled trials showed that the incidence of
Incidence of clinical malaria and hospital admissions clinical malaria and hospital admissions and the risk of
and the risk of anaemia did not diﬀer between groups in anaemia were lower in infants assigned to ITP with
either of the potential rebound periods (tables 3 and 4, sulfadoxine-pyrimethamine than in those assigned to
see table 2 for deﬁnitions). [A: edit ok?] Similar results placebo. Other trials of intermittent treatment were not
were found in the sensitivity analysis (table 4).
40 included in this analysis because they used diﬀerent
There were 56 deaths (1·4%) in the IPT group compared drugs and did not deliver IPT at the same time as EPI
with 53 (1·3%) in the placebo group (rate ratio 1·05, 95% vaccines,23 used IPT as a treatment for anaemia in
CI 0·72–1·54, p=0·79). There was moderate statistical children,24,25 or gave IPT with monthly intervals to
heterogeneity in the number of deaths between trials schoolchildren26 or children up to 5 years or 10 years of
(I²=24·6%). One death, in the IPT group of the trial in 45 age in settings with highly seasonal transmission of
Kumasi, was classiﬁed as possibly caused by study malaria.27–29 [A: edit ok (ie, were the schoolchildren in ref
treatment [A: ok, rather than IPT? Were assignment 26 given IPT at monthly intervals)?]
groups still masked when classiﬁed?], since it occurred
None of the individual trials had suﬃcient power to
19 days after a treatment dose (table 5). At the visit after assess the eﬀect of IPT on mortality. However, our metaadministration of the second dose at 9 months of age, 50 analysis found that the overall number of deaths did not
malaria was conﬁrmed by microscopy and the infant diﬀer between groups, suggesting that IPT does not
received amodiaquine, and iron and folic acid reduce mortality compared with placebo. All the studies
supplementation. 2 weeks later, the infant became very provided study participants with good access to curative
weak, was admitted to hospital, given a blood transfusion services, which, combined with intensive follow-up in
for severe anaemia, and received penicillin, artesunate, 55 some studies, might account for the low crude mortality
paracetamol, iron, and folic acid. The infant was rates recorded in the trials. Our eﬃcacy estimates might
discharged 6 days later in an apparently satisfactory therefore underestimate the potential eﬀect of IPT on
Protective eﬃcacy
(% [95% CI])

6

Protective eﬃcacy
(% [95% CI])

Weight (%)

1
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Placebo
Events

1

IPT
PYAR*

Incidence
per PYAR

Events

PYAR*

Incidence
per PYAR

Combined estimates
Pooled estimate of
protective eﬃcacy†
(% [95% CI])

Sensitivity analysis§
I2‡

p value

Pooled estimate of
protective eﬃcacy†
(% [95% CI])

p value

Trial removed

5

From dose 1 until 12 months of age
Clinical malaria
Primary deﬁnition¶

2257

2598

0·87

1658

2625

0·63

30·3% (19·8 to 39·4)

61·8

<0·0001

25·9% (19·6, 31·7)

??

Ifakara8

Locally deﬁned cutoﬀ density||

1473

2632

0·56

1048

2651

0·40

32·9% (21·8 to 42·4)

53·7

??

27·7% (20·2 to 34·5)

??

Ifakara8

656

2671

0·25

467

2684

0·17

29·9% (19·3 to 39·1)

0

??

27·4% (16·1 to 37·3)

??

Ifakara8

All-cause hospital
admissions

898

2776

0·32

714

2783

0·26

22·9% (10·0 to 34·0)

33·5

0·001

20·6% (9·8 to 30·1)

??

Tamale12

Hospital admissions
associated with malaria
parasitaemia††

233

2477

0·09

141

2480

0·06

38·1% (12·5 to 56·2)

49·6

0·007

31·4% (–0·4 to 53·1)

??

Ifakara8

Anaemia (reduced risk of
ﬁrst or only episode)‡‡

656

3963

0·17

526

3948

0·13

21·3% (8·2 to 32·5)

46·9

0·002

18·7% (6·2 to 29·5)

??

Ifakara8

0·12

73·1% (60·9 to 81·4)

0

??

72·4% (59·6 to 81·2)

??

Tamale12

High-density cut-oﬀ**

10

15

Against clinical malaria (primary deﬁnition) on diﬀerent follow-up times
Prophylactic eﬀect§§
I (after dose at
3 months of age)

152

341

0·45

42

344

II (after dose at
9 months of age)

309

307

1·00

87

323

0·27

79·7% (60·1 to 89·7)

79·8

??

71·3% (51·0 to 83·2)

??

Tamale12

III (after dose at 12 or
15 months of age)

237

207

1·14

95

224

0·42

73·5% (31·3 to 89·8)

87·6

??

59·8% (5·4 to 82·9)

??

Tamale12

Inter-dose eﬀect
period¶¶

1185

1294

0·92

1054

1298

25
0·81

12·1% (2·2 to 21·0)

5·7

??

10·8% (1·1 to 19·6)

??

Ifakara8

Potential rebound
period I||||

1264

1405

0·90

1166

1415

0·82

9·5% (0·3 to 17·8)

0

0·044

8·0% (–1·7 to 16·7)

??

Ifakara8

1491

1368

1·09

1502

1370

1·10

–1·0% (–11·9 to 8·7)

18

0·843

–3·9% (–13·9 to 5·2)

??

Ifakara8

All-cause hospital
admissions

404

1408

0·29

413

1470

0·28

–2·7% (–20·2 to 12·1)

0

0·735

–6·6% (–25·9 to 9·6)

??

Tamale12

Hospital admissions
associated with malaria
parasitaemia

105

1308

0·08

124

1302

1·0

–20·2% (–59·3 to 9·3)

0

0·199

–28·2% (–74·7 to 6·0)

??

Ifakara8

Anaemia (reduced risk
of ﬁrst or only episode)

531

3839

0·14

522

3821

2·1% (–8·0 to 11·2)

0

0·673

0·9% (–9·5 to 10·2)

??

Ifakara8

20

Potential rebound period II***
Clinical malaria
(primary deﬁnition)

30

35

0·14

PYAR=person-years at risk. IPT=intermittent preventive treatment. *Apart from anaemia, where the total number of children at risk is presented. †Protective eﬃcacy deﬁned as (1–RR)×100. ‡Proportion of the
variation attributable to heterogeneity is presented as I2. §The sensitivity analysis removes the trial with the highest protective eﬃcacy from table 3. ¶Primary deﬁnition: history of fever or measured fever with
any P falciparum parasitaemia. History of fever included reported fever during the past 24 h in the trials in Ifakara and Manhiça, and during the past 48 h for the other four trials. Measured fever was deﬁned as an
40
axillary temperature 37·5°C or more for the trials in Ifakara, Navrongo, Tamale, and Manhiça; rectal or tympanic temperature 38°C or more for the trial in Kumasi, and 38·5°C or more for the trial in Lambaréné.
||A history of fever, or measured fever, with a minimum P falciparum parasite density for each site chosen to have a speciﬁcity of more than 90%; trials in Ifakara, Manhiça, and Kumasi more than 500 parasites per
µL; trial in Lambaréné more than 600 parasites per µL; trial in Tamale more than 5000 parasites per µL; trial in Navrongo more than 8000 parasites per µL. **Episodes with a history of fever or measured fever
with P falciparum parasitaemia more than 20 000 parasites per µL. ††Admissions to a paediatric ward with any P falciparum parasitaemia irrespective of symptoms suggestive of malaria or a clinical diagnosis of
malaria. ‡‡Packed-cell volume less than 25% in trials in Ifakara, Navrongo, and Manhiça and a haemoglobin concentration less than 80 g/L in trials in Kumasi, Lambaréné, and Tamale. §§For deﬁnitions see
table 2. ¶¶From 35 days after dose at 3 months or 4 months of age until dose at 9 months of age. ||||From 35 days after the dose at 9 months of age up to the next dose of IPT or age 15 months. ***5-month
45 [A: incidence has been added, so that readers can compare IPT and placebo more easily. Please check that these
period starting 35 days after last dose. [A: please check all footnotes are cited correctly]
ﬁgures are correct] [A: please check p values added and provide the missing values]

Table 4: Combined estimates and sensitivity analysis|

mortality in populations with poor access to curative 50 safety and eﬃcacy outcomes to the analysis at 12 months
health services. Although IPT did not aﬀect mortality of age.
rates, it was associated with a reduced incidence of illness
Careful assessment of safety is important when
suﬃciently severe to warrant hospital admission, preventive interventions are being evaluated, since those
reﬂecting a potential of IPT to save lives. A pooled given to healthy individuals need to have very high
analysis of safety and eﬃcacy at 3 months after the last 55 beneﬁt-to-harm ratios. None of the serious dermatological
dose given (ie, including doses given between 12 months adverse events in the IPT group was associated with
and 24 months) in four of the six trials showed similar study treatment. However, there was one suspected case
www.thelancet.com Vol 374
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were highly unlikely to be Stevens–Johnson syndrome,30
because the syndrome is a severe disorder that requires
Events
Number of events
Events
Number of events
intensive care, is associated with a high case-fatality rate,
possibly related to
possibly related to
and a patient with the syndrome who is not admitted to
treatment
treatment
5 hospital in a rural African setting is unlikely to recover.
Deaths (number of deaths/number of infants [%]) [A1]
Large-scale implementation studies of IPT with
Ifakara
5/350 (0·9%)
0
10/351 (2·8%)
0
sulfadoxine-pyrimethamine in infants are being done by
Navrongo *
22/1221 (1·8%) 0
11/1225 (0·9%)
0
the IPTi Consortium in Tanzania and by UNICEF in six
Manhiça
20/748 (2·7%)
0
22/755 (2·9%)
0
other African countries [A: are there references for
Kumasi
3/535 (0·6%)
1
3/535 (0·6%)
0
10 these?]. Across these studies, more than 250 000 infants a
Tamale
6/600 (1·0%)
0
7/599 (1·2%)
0
year are receiving three doses of IPT alongside routine
Lambaréné
0/504 (0%)
0
0/507 (0%)
0
vaccination delivered by the EPI. So far, no serious
Total
56/3958 (1·4%) 1
53/3972 (1·3%)
0
adverse events related to IPT have been reported to the
Non-fatal hospital admissions (number of admissions/PYAR [incidence per PYAR])
consortium safety panel (Schellenberg D, unpublished
Ifakara
106/248 (0·43)
0
151/251 (0·60)
0
15 data;
de Sousa A, [A: aﬃliation?], personal
Navrongo *
248/874 (0·28)
0
309/867 (0·26)
0
communication). Data obtained in the trials in Manhiça
Manhiça
227/495 (0·46)
0
279/487 (0·57)
0
and Navrongo suggest that IPT with sulfadoxineKumasi †
46/386 (0·12)
1
52/389[A3] (0·13) 2
pyrimethamine has no adverse eﬀect on serological
Tamale
23/402 (0·06)
1
52/401 (0·13)
1
responses to vaccines for polio, hepatitis B, measles, or
Lambaréné
26/327 (0·08)
2
17/330 (0·05)
2
20 diphtheria, tetanus, and pertussis (DTP),9,10 and there are
Total [A2]
676
4
860
5
reassuring data on yellow fever vaccination [A: what do
Serious dermatological adverse events (number of events/PYAR [incidence per PYAR])
you mean here—there is less convincing evidence for
Ifakara
0/248
0
0/251
0
yellow fever vaccines, or that the evidence is from the
Navrongo *
··
··
following report? Please rephrase to clarify] (Interim
Manhiça
2/495 (0·004) 0
7/487 (0·01)
0
25 report on IPTi with SP, WHO Advisory Committee on
serological responses to EPI vaccines in infants receiving
Kumasi
0/386
0
2/398 [A3] (0·005) 1
IPTi, WHO Internal Report 2006 [A: is this report in the
Tamale
0/402
0
2/401 (0·005)
0
public domain? If so, we would prefer to add to the
Lambaréné
1/327 (0·003) 0
2/330 (0·006)
0
reference list]).
Total [A2]
3
0
13
1
30 The individual trials reported diﬀerent ﬁndings for
IPT=intermittent preventive treatment. PYAR=person-years at risk. ··=data not available. *In the trial in Navrongo,
various extended follow-up periods after the last dose of
no deaths or serious dermatological adverse events were judged related to treatment, but no more details are
IPT or placebo. Sustained protection against clinical
available. †In the trial in Kumasi, three hospital admissions in the sulfadoxine-pyrimethamine group and two in the
placebo group were not assessable to work out causality. [A1: percentages and incidences have been added, so that
malaria was seen up to the age of 2 years in children
readers can compare IPT and placebo more easily. Please check that these ﬁgures are correct] [A2: why is the
assigned to IPT in the trial in Ifakara.31 In children aged
denominator not present?] [A3: person-years at risk diﬀer in this trial (389 for hospital admissions, 398 for
35 between 16 months and 24 months in Navrongo,
SAEs), which is correct?]
incidence of clinical malaria with a parasite density more
Table 5: Deaths, non-fatal hospital admissions, and serious dermatological adverse events up to
than 5000 per µL was higher in the IPT group than in the
12 months of age, or 3 months after the last dose of study treatment received, whichever is earlier
placebo group. In the trial in Kumasi, the number of
episodes of anaemia (haemoglobin <75 g/L) during the
of Stevens–Johnson syndrome in the placebo group of 40 8-month period starting 5 weeks after the last dose at
the trial in Kumasi. Two further possible cases of this 15 months of age was higher in the ITP group than in the
syndrome have also been reported in children from the placebo group; however, this diﬀerence was not seen
same site, after they received a third dose of IPT [A: please with deﬁnitions of anaemia of haemoglobin 70 g/L or
conﬁrm they were in the IPT group and not the placebo 80 g/L. In the trial in Tamale, the risk of severe malarial
group] at 15 months of age.11 Both children recovered 45 anaemia (haemoglobin <50 g/L) during the 8-month
without admission to hospital and presented to the study period starting 1 month after the last IPT dose at
team in the convalescent phase. The study team erred on 15 months of age in children assigned to IPT was about
the side of caution and reported suspected Stevens– double the risk in children assigned to placebo. There
Johnson syndrome, although the diagnosis has not been was no evidence of either sustained protection or of
conﬁrmed (May J, personal communication). After a 50 increased risk during extended follow-up in the trials in
review of the existing information, reports, and a Lambaréné and Manhiça. [A: this section is a little
photograph of one of the cases, the consortium safety diﬃcult to read and understand. Can you rephrase or
panel judged these two cases as unlikely to be present the results in a diﬀerent way?]
Stevens–Johnson syndrome. IPT data, including the
Even though ﬁndings have not been consistent across
pooled analyses for safety and eﬃcacy, were reviewed by 55 diﬀerent endpoints within or between trials, they have
a panel of experts convened by the US Institute of raised concerns that IPT in infants might impair the
Medicine. The experts also concluded that these cases development of naturally acquired immunity to malaria.
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In the 5-month period starting 35 days after the last dose 1
Protective eﬃcacy
Protective eﬃcacy
Weight (%)
(% [95% CI])
(% [95% CI])
(ie, after treatment completion), [A: correct?] the incidence
of hospital admissions associated with malaria
Ifakara
29·0 (–4·2 to 51·6)
6·4
parasitaemia was higher in the IPT group than in the
placebo group; however, the pooled eﬀect estimate did 5 Navrongo
–3·4 (–29·3 to 17·5)
18·6
not reach statistical signiﬁcance and there were no
22·8
Manhiça
7·4 (–13·4 to 24·4)
signiﬁcant increases in incidence of clinical malaria or
Kumasi
7·8 (–9·1 to 22·1)
33·1
all-cause hospital admissions, or in risk of anaemia
during this period. These ﬁndings contrast with the
Tamale
19·6 (–2·2 to 36·7)
16·3
protective eﬀect seen against these endpoints during the 10
Lambaréné
12·7 (–54·9 to 50·8)
2·9
intervention period and, thus, the balance of risks and
beneﬁts seem to favour IPT. Nevertheless, monitoring of
Overal protective eﬃcacy
9·5 (0·3 to 17·8)
100·0
morbidity should be part of studies of eﬀectiveness and
phase IV studies in which IPT in infants is implemented.
50
75
100
–100
–75
–50
–25
0
25
A pooled analysis for a possible rebound eﬀect was done 15
Favours placebo
Favours IPT
for those trials with extended follow-up periods (Ifakara,
Manhiça, Lambaréné, and Navrongo); outcomes did not Figure 3: Combined estimates for the protective eﬃcacy of IPT with sulfadoxine-pyrimethamine in infants
clinical malaria from 35 days after the dose at 9 months of age until next dose or 15 months of age
diﬀer between IPT and placebo groups in the 11-month against
The width of the diamond represents the 95% CI interval in the overall pooled protective eﬃcacy estimate.
period starting 35 days after the last dose (data not [A: vertical line moved to 0%. Ok?]
shown).
20
The ﬁrst trial of IPT in infants, undertaken in Ifakara, of curative eﬃcacy to inform the use of antimalarial For the pooled analysis of the
showed high protective eﬃcacy of the intervention. drugs for prevention where infections might be of low extended follow-up period see
http://www.ipti-malaria.org
Because of these results, additional trials were done; density and asymptomatic [A: meaning of highlighted
however, they reported lower estimates of protective sentence unclear; please rephrase]. Moreover, the
eﬃcacy. Protective eﬃcacy against clinical malaria was 25 increasing use of artemisinin-based combination therapy
similar between trials during all periods analysed, apart will lead to a reduction in the use of sulfadoxinefrom during the inter-dose period, when eﬃcacy was pyrimethamine, reducing the spread of resistance and
higher in the trial in Ifakara than in the other trials. prolonging the duration for which this drug combination
Because of the diﬀerences in trial design between the six could be useful for IPT. A corresponding concern is that
studies, we were unable to draw conclusions about the 30 IPT with sulfadoxine-pyrimethamine in infants might
conditions under which IPT in infants might have the facilitate the spread of drug resistance. Although the
best possible eﬀect. However, a detailed comparison prevalence of markers of resistance to sulfadoxinebetween very similar trials in Ifakara and Manhiça32 pyrimethamine increases after doses in infants,35,36
suggested that the combined use of insecticide-treated mathematical models suggest that the size of such eﬀect
bednets and IPT might explain the higher eﬃcacy 35 in the global spread of resistance will be small.37 At
reported in the Ifakara trial. Nevertheless, when present, sulfadoxine-pyrimethamine is the only
sulfadoxine-pyrimethamine and artesunate were antimalarial drug available for IPT in both pregnancy
coadministered as IPT in a trial in western Kenya, where and infancy, in view of the combination’s long half-life
use of insecticide-treated bednets was very high, eﬃcacy and prophylactic eﬀect, established safety proﬁle,
[A: against clinical malaria?] was less than 30% 40 acceptability,7,38 and aﬀordability. IPT seems to work by
(Newman R, Slutsker L, unpublished data).
prophylaxis, with sulfadoxine-pyrimethamine providing
Parasite resistance to sulfadoxine-pyrimethamine has protection for up to 6 weeks in infants.39,40 New longspread across Africa, which could undermine the eﬃcacy acting antimalarial drugs are urgently needed for use in
of IPT in infants. The highest reported frequency of IPT in infants.
resistance during the trials was 31% (as measured by the 45 Where malaria transmission is highly seasonal and
WHO standard day 14 in-vivo clinical and parasitological severe malaria occurs rarely in infants, methods for
resistance in 6–59-month-old symptomatic children). delivering IPT to older children might be needed.41
This level of resistance, which corresponds with However, in areas with a substantial burden of malaria in
intermediate levels as deﬁned by ter Kuile and infants, delivery of IPT through WHO’s EPI system has
colleagues,33 did not preclude protective eﬃcacy when 50 been shown to be highly cost eﬀective.42
sulfadoxine-pyrimethamine was used for IPT in infants.
[A: please provide a brief paragraph discussing the
Furthermore, the site with the highest level of resistance limitations of your analysis]
to the drug combination (Ifakara)34 had the highest
This pooled analysis substantiates the notion that IPT
eﬃcacy of IPT, and in all trials (apart from in Lambaréné is safe and eﬃcacious in infants. Furthermore, operational
and after the last dose of IPT in Kumasi), there was 55 experience from Tanzania43 and six other African
signiﬁcant protection in the month after an IPT dose. countries [A: reference?] shows that rapid large-scale
These ﬁndings call into question the value of estimates deployment of IPT is feasible. Thus, this intervention
www.thelancet.com Vol 374
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could make an important contribution to reducing the
intolerable burden of malaria in infants and should be
integrated with other eﬀective control methods.32,44–50
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